In November 2016, while hearing a related case, the Delhi High Court reportedly directed the Union Government to finalize and implement a policy on rare diseases, with a provision for free treatment with the expensive medications, as will be required by … Continue reading
Tag Archives: OSDD
Awaiting The Two To Tango: Pharma Innovation And Public Health Interest
“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform – Balancing Affordability with Incentives for Innovation’, … Continue reading
A Potential Game Changer For Pharma R&D
The ghost of ‘Patent Cliff’ has been haunting the ‘Big Pharma’ since quite some time. This situation has been further aggravated by cost containment pressures of various Governments both in the developed and the emerging markets together with contentious issues … Continue reading
R&D: Is Indian Pharma Moving Up the Value Chain?
It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment … Continue reading
Open Innovation: Quo Vadis, Pharmaceutical R&D?
Is the Pharmaceutical R&D moving from the traditional models to much less uncharted frontiers? Perhaps towards this direction, in November, 2010 in a report titled, “Open Source Innovation Increasingly Being Used to Promote Innovation in the Drug Discovery Process and … Continue reading
From Cross-Licensing to ‘Patent Pools’ and… India: Will there be a ground swell?
Since many years, the global pharmaceutical industry has been making effective commercial use of cross-licensing, however, by and large, the industry still does not seem to be quite in favor of ‘Patent Pools’ for various reasons. The ‘Patent Pool’, as … Continue reading
Open Source Drug Discovery (OSDD) initiative for the tropical diseases by CSIR and cancer by GlaxoSmithKline deserves a big applaud and support from all concerned.
As the name suggest the ‘Open Source Drug Discovery (OSDD)’ is an open source code model of discovering a New Chemical Entity (NCE) or a New Molecular Entity (NME). In this model all data generated related to the discovery research will be … Continue reading
‘Patent Pool’ – is GSK setting a new trend for the global pharmaceutical industry?
On February 13, 2009, The Guardian reported that Andrew Witty, CEO of GlaxoSmithKline (GSK) announced some significant changes to the way his company will operate in the developing countries of the world. GSK, as Witty said, will: • “Cut its … Continue reading